LSM10

Across TCGA pan-cancer cohorts, LSM10 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LSM10 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LSM10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LSM10 expression acts as an unfavorable survival marker.

LUAD, LUSC, and STAD are the cancer types where LSM10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.036	0.791	<.001	18	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
STAD	OS	Median	All	0.178	0.583	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LSM10–LUAD (DFS)

Open the LUAD breakdown →